7.89 USD
-1.64 (-17.21%)
8.34 USD
+0.45 (+5.7%)
Overall INBS gets a fundamental rating of 1 out of 10. We evaluated INBS against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of INBS have multiple concerns. INBS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
INBS had negative earnings in the past year.
INBS had a negative operating cash flow in the past year.
INBS had negative earnings in each of the past 5 years.
In the past 5 years INBS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -108.25%, INBS is doing worse than 81.62% of the companies in the same industry.
INBS has a worse Return On Equity (-300.07%) than 77.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -108.25% | ||
| ROE | -300.07% | ||
| ROIC | N/A |
ROA(3y)-101.5%
ROA(5y)-80.79%
ROE(3y)-251.51%
ROE(5y)-185.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of INBS (43.09%) is worse than 65.41% of its industry peers.
INBS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
INBS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, INBS has more shares outstanding
Compared to 1 year ago, INBS has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -5.34, we must say that INBS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.34, INBS is not doing good in the industry: 70.27% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.04 indicates that INBS is not too dependend on debt financing.
INBS's Debt to Equity ratio of 0.04 is fine compared to the rest of the industry. INBS outperforms 68.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.34 |
ROIC/WACCN/A
WACC9.75%
2.3 Liquidity
INBS has a Current Ratio of 0.89. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of INBS (0.89) is worse than 88.11% of its industry peers.
A Quick Ratio of 0.76 indicates that INBS may have some problems paying its short term obligations.
INBS has a Quick ratio of 0.76. This is amonst the worse of the industry: INBS underperforms 84.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
INBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.16%, which is quite impressive.
INBS shows a small growth in Revenue. In the last year, the Revenue has grown by 3.27%.
Measured over the past years, INBS shows a very strong growth in Revenue. The Revenue has been growing by 74.49% on average per year.
EPS 1Y (TTM)54.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-395.27%
Revenue 1Y (TTM)3.27%
Revenue growth 3Y91.13%
Revenue growth 5Y74.49%
Sales Q2Q%27.5%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y128%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year126.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for INBS. In the last year negative earnings were reported.
INBS is valuated rather expensively with a Price/Forward Earnings ratio of 22.10.
Compared to the rest of the industry, the Price/Forward Earnings ratio of INBS indicates a somewhat cheap valuation: INBS is cheaper than 77.30% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.23. INBS is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.1 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for INBS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
7.89
-1.64 (-17.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners13.6%
Inst Owner Change0%
Ins Owners0.57%
Ins Owner Change0%
Market Cap74.56M
Revenue(TTM)3.29M
Net Income(TTM)-10.87M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short Ratio3.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-79.05%
Min Revenue beat(2)-80.72%
Max Revenue beat(2)-77.38%
Revenue beat(4)0
Avg Revenue beat(4)-77.54%
Min Revenue beat(4)-80.72%
Max Revenue beat(4)-73.53%
Revenue beat(8)0
Avg Revenue beat(8)-58.65%
Revenue beat(12)0
Avg Revenue beat(12)-49.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.1 | ||
| P/S | 22.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 20.59 | ||
| P/tB | 504.13 | ||
| EV/EBITDA | N/A |
EPS(TTM)-12.81
EYN/A
EPS(NY)0.36
Fwd EY4.52%
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.35
BVpS0.38
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -108.25% | ||
| ROE | -300.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.09% | ||
| FCFM | N/A |
ROA(3y)-101.5%
ROA(5y)-80.79%
ROE(3y)-251.51%
ROE(5y)-185.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | -5.34 |
F-Score3
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-395.27%
EPS Next Y128%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.27%
Revenue growth 3Y91.13%
Revenue growth 5Y74.49%
Sales Q2Q%27.5%
Revenue Next Year126.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.17%
OCF growth 3YN/A
OCF growth 5YN/A
INTELLIGENT BIO SOLUTIONS IN / INBS FAQ
Can you provide the ChartMill fundamental rating for INTELLIGENT BIO SOLUTIONS IN?
ChartMill assigns a fundamental rating of 1 / 10 to INBS.
What is the valuation status of INTELLIGENT BIO SOLUTIONS IN (INBS) stock?
ChartMill assigns a valuation rating of 2 / 10 to INTELLIGENT BIO SOLUTIONS IN (INBS). This can be considered as Overvalued.
How profitable is INTELLIGENT BIO SOLUTIONS IN (INBS) stock?
INTELLIGENT BIO SOLUTIONS IN (INBS) has a profitability rating of 0 / 10.
What is the earnings growth outlook for INTELLIGENT BIO SOLUTIONS IN?
The Earnings per Share (EPS) of INTELLIGENT BIO SOLUTIONS IN (INBS) is expected to grow by 128% in the next year.